- •In an abscopal response, tumor regression occurs at a distant metastatic site following local radiation treatment.
- •Radiation therapy can prime the immune system by creating a T-cell mediated response that acts locally and distally.
- •Immune checkpoint blockade may synergize with radiotherapy to enhance local tumor control and systemic response.
- •Prospective trials will evaluate the combination of radiation and immunotherapy in the definitive and metastatic setting.
- •Th optimal timing, radiation dose, and technique in combination with immunotherapy have yet to be determined.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- PD-1 blockade in tumors with mismatch-repair deficiency.N. Engl. J. Med. 2015; 372: 2509-2520
- FDA approves pembrolizumab for advanced cervical cancer with disease progression during or after chemotherapy.([cited 2018 October 27]; Available from)
. Hamanishi, J., et al., Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. U. S. A., 2007. 104(9): p. 3360–5.
Zhang, L., et al., Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med., 2003. 348(3): p. 203–13.
Sato, E., et al., Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. U. S. A., 2005. 102(51): p. 18538–43.
Nielsen, J.S., et al., CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin. Cancer Res., 2012. 18(12): p. 3281–92.
Brahmer, J.R., et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med., 2012. 366(26): p. 2455–65.
Hamanishi, J., et al., Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol., 2015. 33(34): p. 4015–22.
Disis, M.L., et al., Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: a phase Ib, open-label expansion trial. J. Clin. Oncol., 2015. 33(15_suppl): p. 5509–5509.
Matulonis, U.A., et al., Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: interim results from the phase 2 KEYNOTE-100 study. J. Clin. Oncol., 2018. 36(15_suppl): p. 5511–5511.
Burger, R.A., et al., The addition of a CTLA4 targeted therapy to a PD-1 targeted therapy could benefit women with ovarian cancer, in Biennial Meeting of the International Gynecologic Cancer Society (IGCS). 2018: (Kyoto, Japan).
Howitt, B.E., et al., Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulva. JAMA Oncol, 2016. 2(4): p. 518–22.
Chung, H.C., et al., Pembrolizumab treatment of advanced cervical cancer: updated results from the phase 2 KEYNOTE-158 study. J. Clin. Oncol., 2018. 36(15_suppl): p. 5522–5522.
- Integrated genomic characterization of endometrial carcinoma.Nature. 2013; 497: 67-73
- Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1.JAMA Oncol. 2015; 1: 1319-1323
- Radiation-induced cell death mechanisms.Tumour Biol. 2010; 31: 363-372
- Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma.J. Natl. Cancer Inst. 1979; 63: 1229-1235
Sharabi, A.B., et al., Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol, 2015. 16(13): p. e498–509.
- Whole body irradiation; radiobiology or medicine?.Br. J. Radiol. 1953; 26: 234-241
Siva, S., et al., Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett., 2015. 356(1): p. 82–90.
- Systematic review of case reports on the abscopal effect.Curr. Probl. Cancer. 2016; 40: 25-37
- Spontaneous regression of pleural metastases after nephrectomy for renal cell carcinoma—a histologically verified case with nine-year follow-up.Scand. J. Urol. Nephrol. 2002; 36: 396-398
- Jr., Spontaneous regression of primary malignant melanomas with regional metastases.Cancer. 1965; 18: 1399-1415
Takaya, M., et al., Abscopal effect of radiation on toruliform para-aortic lymph node metastases of advanced uterine cervical carcinoma–a case report. Anticancer Res., 2007. 27(1B): p. 499–503.
Postow, M.A., et al., Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med., 2012. 366(10): p. 925–31.
- Repeated abscopal effect with radiotherapy and programmed death 1 blockade in mismatch repair–deficient endometrial cancer.JCO Precis Oncol. 2018; : 1-6
Sharabi, A., et al., Exceptional response to nivolumab and Stereotactic Body Radiation Therapy (SBRT) in neuroendocrine cervical carcinoma with high tumor mutational burden: management considerations from the center for personalized cancer therapy at UC San Diego Moores Cancer Center. Oncologist, 2017. 22(6): p. 631–637.
Chajon, E., et al., The synergistic effect of radiotherapy and immunotherapy: a promising but not simple partnership. Crit Rev Oncol Hematol, 2017. 111: p. 124–132.
- Transforming growth factor-beta and the immune response: implications for anticancer therapy.Clin. Cancer Res. 2007; 13: 5262-5270
- Current clinical trials testing the combination of immunotherapy with radiotherapy.J Immunother Cancer. 2016; 4: 51
Sharabi, A.B., et al., Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncology (Williston Park, NY), 2015. 29(5).
Sharabi, A.B., et al., Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncology (Williston Park), 2015. 29(5): p. 331–40.
Twyman-Saint Victor, C., et al., Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature, 2015. 520(7547): p. 373–7.
- The promise of the abscopal effect and the future of trials combining immunotherapy and radiation therapy.Int. J. Radiat. Oncol. Biol. Phys. 2016; 95: 1254-1256
Huang, A.C., et al., T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature, 2017. 545(7652): p. 60–65.
- Radiation as an immunological adjuvant: current evidence on dose and fractionation.Front. Oncol. 2012; 2: 153
Deng, L., et al., Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest., 2014. 124(2): p. 687–95.
Kwon, E.D., et al., Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol, 2014. 15(7): p. 700–12.
. Beer, T.M., et al., Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J. Clin. Oncol., 2017. 35(1): p. 40–47.
Luke, J.J., et al., Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J. Clin. Oncol., 2018. 36(16): p. 1611–1618.
Shaverdian, N., et al., Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol, 2017. 18(7): p. 895–903.
Antonia, S.J., et al., Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N. Engl. J. Med., 2017. 377(20): p. 1919–1929.
Antonia, S.J., et al., Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med., 2018.
Mayadev, J., et al., A phase I study of sequential ipilimumab in the definitive treatment of node positive cervical cancer: GOG 9929. J. Clin. Oncol., 2017. 35(15_suppl): p. 5526–5526.
Creutzberg, C.L., et al., Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol. Oncol., 2003. 89(2): p. 201–9.
Charra-Brunaud, C., et al., Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study. Radiother. Oncol., 2012. 103(3): p. 305–13.
Potter, R., et al., The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol, 2018. 9: p. 48–60.
Dewan, M.Z., et al., Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res., 2009. 15(17): p. 5379–88.
Farooque, A., et al., Low-dose radiation therapy of cancer: role of immune enhancement. Expert. Rev. Anticancer. Ther., 2011. 11(5): p. 791–802.
- Immune-related adverse events associated with immune checkpoint blockade.N. Engl. J. Med. 2018; 378: 158-168
Larkin, J., et al., Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med., 2015. 373(1): p. 23–34.
Verma, V., et al., Toxicity of radiation and immunotherapy combinations. Adv Radiat Oncol, 2018. 3(4): p. 506–511.
Bang, A., et al., Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 2017. 98(2): p. 344–351.